Maternal and Neonatal Outcomes After Rituximab (RTX) Exposure During Pregnancy: A Systematic Review (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0971; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Pooled rates were 4% for congenital anomalies and neonatal infections, and 3.5% for neonatal mortality. Certainty of evidence of all outcomes was judged to be very low Conclusion Maternal outcomes after RTX exposure in pregnancy likely reflect the underlying indication, and neonatal outcomes appear reassuring; very low certainty of evidence limits definitive conclusions"
Review • Infectious Disease
|
|
Sahar Koubar; Mallak Zatreh; Sara Saleh Jdiaa; Shreepriya Mangalgi; Muayad Azzam; Mayssaa Hoteit; Reem Adel Mustafa
|